Back to top

Image: Bigstock

ImmuCell Q3 Earnings Rebound as Sales Surge and Margins Expand Y/Y

Read MoreHide Full Article

Shares of ImmuCell Corporation (ICCC - Free Report) have gained 10.4% since the company reported its earnings for the third quarter of 2026. This compares to the S&P 500 Index’s 3.7% decline over the same period. Over the past month, the stock has risen 7.7%, outperforming the S&P 500’s 5.4% fall.

ImmuCell reported third-quarter 2026 earnings of 10 cents per share, reversing a loss of 2 cents in the year-ago quarter. Product sales increased 46% year over year to $8.04 million from $5.51 million in the prior-year quarter. Net income reached $953,000 compared to a net loss of $140,000 a year earlier. The improvement reflected stronger product demand, increased manufacturing output and higher pricing.

ImmuCell Corporation Price, Consensus and EPS Surprise

ICCC's Other Key Financial Metrics

Gross profit increased 50.4% year over year to $3.56 million from $2.36 million in the prior-year quarter. Gross margin expanded 130 basis points to 44.2% from 42.9%.

Operating income rose to $958,000 from $20,000 in the prior-year quarter, while operating margin improved to 11.9% from 0.4%.

Adjusted EBITDA surged 151.2% to $1.88 million from $750,000 in the prior-year quarter.

Sales, marketing and administrative expenses increased 46.8% to $2.42 million, reflecting investments in leadership and commercial expansion. Conversely, product development expenses declined 74.5% to $177,000.

Cash and cash equivalents jumped to $7.91 million as of Sept. 30, 2026 from $3.81 million as of Dec. 31, 2025. Net working capital increased to $16.9 million from $13 million, while stockholders' equity rose to $32.8 million from $27.1 million.

ICCC's Management Commentary

CEO Olivier te Boekhorst attributed the quarterly performance to the company's renewed focus on First Defense, improved product availability and expanding commercial activities.

The commercial team expanded from nine to 13 employees since November 2025, strengthening customer engagement. New customers contributed approximately 46% of third-quarter net sales growth, while increased purchases from existing customers accounted for the remaining 54%.

Management highlighted improving manufacturing productivity, with average monthly output reaching approximately 435,000 manufacturing units in 2026, up 14% from 2025.

The company also reported encouraging progress in its functional feed product line, having achieved its full-year sales targets ahead of schedule.

Factors Influencing ICCC's Results

Revenue growth benefited partly from the absence of distributor restocking challenges that affected the prior-year quarter.

Domestic sales increased 29.2% to $6.9 million, while international revenues surged 573% to $1.1 million, primarily supported by Canadian shipments following the clearance of earlier backorders.

Distributor out-the-door volumes grew 18% year over year, indicating stronger underlying customer demand.

Higher pricing, improved manufacturing yields and reduced production waste supported gross margin expansion. However, approximately $400,000 of expenses previously associated with Re-Tain development shifted to the cost of goods sold, reducing reported gross margin by approximately 480 basis points.

Management also highlighted rising colostrum sourcing costs and increased competition for supplies as operational challenges.

ICCC's Expansion Plans and Outlook

ImmuCell reiterated its $8 million manufacturing capacity expansion plan, including $3.5 million for freeze-drying equipment and $4.5 million for colostrum processing.

The freeze-drying expansion is expected to be completed in the first half of 2027, followed by additional processing capacity in the second half.

Management expects these investments to triple manufacturing capacity and reduce production timelines from two to three months to less than a month.

As of Sept. 30, 2026, approximately $1.7 million had been spent on the expansion.

Management expects elevated calf values to support demand for preventive health products through 2027 and 2028. However, the company did not provide specific revenue or earnings guidance.

Other Developments at ICCC

ImmuCell continued restructuring its operations around First Defense following its December 2025 decision to discontinue significant Re-Tain development investments. The company is repurposing former Re-Tain manufacturing assets to support First Defense capacity expansion.

Management also disclosed a minor licensing agreement granting an aquaculture company rights to use certain intellectual property, potentially generating future cash flows.

ImmuCell terminated its at-the-market equity offering and disclosed plans to secure a new $3 million credit facility, replacing its expired $1 million arrangement.

Published in